Genmab AS News - GE9

Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting

Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting...

Genmab Completes Acquisition of ProfoundBio

Genmab Completes Acquisition of ProfoundBio Company Announcement Genmab has completed acquisition of ProfoundBio for USD 1.8 billion in...

Transactions in Connection with Share Buy-back Program

Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; May 21, 2024 – Genmab A/S (Nasdaq: GMAB...

Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress

Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Genmab AS (GE9)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

GE9 News

Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting

Genmab Completes Acquisition of ProfoundBio

Transactions in Connection with Share Buy-back Program

Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress

Transactions in Connection with Share Buy-back Program

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Transactions in Connection with Share Buy-back Program

Genmab Announces Financial Results for the First Quarter of 2024

TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer

Transactions in Connection with Share Buy-back Program Genmab

Transactions in Connection with Share Buy-back Program Genmab

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2024

Transactions in Connection with Share Buy-back Program Genmab

Transactions in Connection with Share Buy-back Program

Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio

GE9 Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Genmab AS (GE9) News

Genmab AS (GE9)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

GE9 News

Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting

Genmab Completes Acquisition of ProfoundBio

Transactions in Connection with Share Buy-back Program

Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress

Transactions in Connection with Share Buy-back Program

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Transactions in Connection with Share Buy-back Program

Genmab Announces Financial Results for the First Quarter of 2024

TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer

Transactions in Connection with Share Buy-back Program Genmab

Transactions in Connection with Share Buy-back Program Genmab

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2024

Transactions in Connection with Share Buy-back Program Genmab

Transactions in Connection with Share Buy-back Program

Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio

GE9 Discussion

Your Recent History